Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers. by Ben Gacem, Riadh et al.
www.elsevier.com/locate/humpath
Human Pathology (2012) xx, xxx–xxxOriginal contribution
Clinicopathologic significance of DNA methyltransferase 1,
3a, and 3b overexpression in Tunisian breast cancers☆
Riadh Ben Gacema, Mohamed Hachana PhDa, Sonia Ziadi MDa,
Soumaya Ben Abdelkarim MDa, Samir Hidar MDb, Mounir Trimeche MD, PhDa,⁎
aDepartment of Pathology, Farhat-Hached Hospital, Sousse 4000, Tunisia
bDepartment of Gynecology and Obstetrics, Farhat-Hached Hospital, Sousse 4000, Tunisia





TunisiaSummary DNA methyltransferase 1, 3a, and 3b affect DNA methylation, and it is thought that they play
an important role in the malignant transformation of various cancers. The current study was designed to
analyze DNA methyltransferase expression by immunohistochemistry in a series of 94 Tunisian
sporadic breast carcinomas. Results were correlated to clinicopathologic parameters and promoter
methylation status of 8 tumor suppressor genes (BRCA1, BRCA2, RASSFA1, TIMP3, CDH1, P16,
RARβ2, and DAPK). Overexpression of DNA methyltransferase 1, 3a, and 3b was detected in 46.8%,
32%, and 44.7% of cases, respectively. A significant correlation was found between DNA
methyltransferase 1 overexpression and Scarff-Bloom-Richardson histologic grade III (P = .01).
DNA methyltransferase 3a overexpression was significantly associated with menopausal status (P =
.01), Scarff-Bloom-Richardson histologic grade III (P = .0001), estrogen (P = .04) and progesterone
(P = .007) receptor negativity, and HER2 overexpression (P = .004). However, DNA methyltransferase
3a overexpression was found less frequently in the luminal A intrinsic breast cancer subtype (9.7%)
than in luminal B (53%), HER2 (41%), and triple-negative (50%) subtypes (P = .001). DNA
methyltransferase 3b overexpression shows significant correlation with promoter hypermethylation of
BRCA1 (P = .03) and RASSFA1 (P = .04) and with the hypermethylator phenotype (more than 4
methylated genes, P = .01). These data suggest that overexpression of various DNA methyltransferases
might represent a critical event responsible for the epigenetic inactivation of multiple tumor suppressor
genes, leading to the development of aggressive forms of sporadic breast cancer.
© 2012 Elsevier Inc. All rights reserved.1. Introduction menstruation, and other factors that have not yet beenBreast cancer is the most common type of cancer in
several parts of the world and the second leading cause of
cancer mortality among all women [1]. Each woman's
breast cancer risk may be higher or lower, depending on
several factors including family history, genetics, age of☆ Conﬂicts of interest: None declared.
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oi:10.1016/j.humpath.2011.12.022identiﬁed [2]. The lack of somatic mutations in sporadic
breast carcinomas suggests that gene inactivation might be
achieved by mechanisms other than coding region muta-
tions, such as epigenetic or regulatory changes [3].
Hypermethylation of the cytosine-phospho-guanine (CpG)
islands of gene promoters is an important epigenetic
mechanism for gene silencing, which may confer a growth
advantage to tumor cells [4]. Many cellular pathways are
inactivated by this epigenetic event, including DNA repair,
cell cycle, apoptosis, cell adherence, and detoxiﬁcation [3].
2 R. Ben Gacem et al.Methylation of cytosine bases in CpG dinucleotides in gene
promoters is coordinated by a family of DNA methyltrans-
ferases (DNMTs) comprising DNMT1, DNMT3a, and
DNMT3b [5]. DNMT1 is the “maintenance”methyltransferase
that ensures faithful transmission of the methylation proﬁle
from maternal to daughter cells during cell division, whereas
DNMT3a and DNMT3b are mainly involved in de novo
establishment of methylation patterns during embryogenesis
[6,7]. Disruption ofDNMT1 inmice results in early embryonic
lethality and severe genomic hypomethylation [8]. Mice
disrupted for DNMT3a or DNMT3b undergo abnormal
mammalian development and have a loss of genomic DNA
methylation in pericentromeric repeats [6].
Overexpression of DNMTs has been reported in various
types of cancers [7,9,10,11,12]. The degree of overexpres-
sion varies between reports depending on the tumor type and
the method of analysis. Many studies have reported that
DNMT expression may have important therapeutic implica-
tions. Indeed, reexpression of promoter-methylated genes
has been obtained with DNMT inhibitor treatment such as 5-
aza-2′deoxycytidine treatment [13-15].
However, few studies have examined the expression of
DNMTs in breast tissues [10,16], and none has evaluated all
3 enzymes simultaneously by immunohistochemistry in
breast tissues. Moreover, no clear relationship between
DNMT overexpression and clinicopathologic parameters has
been established.
Breast cancer rates and median age of onset differ
between Western Europe and North Africa [17]. Compared
with Western populations, Tunisian breast cancer is
characterized by a younger age at onset and a more
aggressive tumor phenotype, especially large tumor size,
high histologic grade, and hormone receptor negativity [18].
These differences may be caused by the discrepancy in
environmental risk factors and/or genetic susceptibilities.
The aims of the current study were to analyze the 3
catalytically active human DNMTs (DNMT1, DNMT3a, and
DNMT3b) for overexpression by immunohistochemistry in a
series of 94 Tunisian breast cancer cases and to seek
relationships between the overexpression of these enzymes,
the clinicopathologic parameters, and hypermethylation
promoters of several tumor suppressor genes.2. Materials and methods
2.1. Patients and tissue samples
Our analysis includes 94 invasive ductal carcinomas
selected from the breast cancer samples collected in the
Department of Pathology, Farhat Hached Hospital of Sousse,
Tunisia. Cases were selected based on the availability of
sufﬁcient parafﬁn-embedded sections and their correspond-
ing frozen tumor biopsy specimens. Familial breast cancer
cases were not included in this study. Patients' age atdiagnosis ranged from 31 to 75 years, with a mean of 48.7
years and a median of 47 years. Tumors were graded
according to the modiﬁed Scarff-Bloom-Richardson (SBR)
system. Clinicopathologic collected information included
patient age, menopausal status, tumor size, SBR histologic
grade, lymph node metastasis, hormonal receptors (estrogen
[ER] and progesterone [PR]), and HER2 status.
Tumors were grouped according to their ER, PR, and
HER2 status into 4 intrinsic subtypes according to Cheang
et al [19]: luminal A (ER+ and/or PR+, and HER2−),
luminal B (ER+ and/or PR+, and HER2+), HER2 over-
expressing (HER2+, and ER− PR−), and triple negative
(ER− PR− HER2−).2.2. Immunohistochemical analysis of
DNMTs expression
The immunohistochemical staining procedure was per-
formed on formalin-ﬁxed, parafﬁn-embedded breast cancer
sections using a rabbit polyclonal anti-DNMT1 antibody
(clone H-300, dilution 1:200; Santa Cruz Biotechnology,
Santa Cruz, CA), a mouse monoclonal anti-DNMT3a
antibody (clone 64B1446, dilution 1:200; Imgenex, San
Diego, CA), and a mouse monoclonal anti-DNMT3b
antibody (clone 52A1018, dilution 1:200; Imgenex). Brieﬂy,
5-μm thick tissue sections were cut, dried overnight at 56°C,
deparafﬁnized in toluene, rehydrated through a series of
alcohol, and washed in Tris-buffered saline (TBS) (0.05
mmol/L Tris–HCl; 1.15 mmol/L NaCl, pH 7.6). For antigen
retrieval, sections were boiled in a water bath with EDTA
buffer (10 mmol/L, pH 8.0) for 40 minutes until the
temperature reached 98°C. Sections were then allowed to
cool at room temperature for 20 minutes, rinsed thoroughly
with water, and placed in TBS. Endogenous peroxidase
activity was blocked with hydrogen peroxide/methanol for 5
minutes. Subsequently, sections were rinsed gently with TBS
and incubated at 4°C overnight with the appropriate primary
antibody. Immunostainings were performed using the high-
sensitive polymer-based EnVision system (DakoCytoma-
tion, Glostrup, Denmark) according to the manufacturer's
instructions. Immunoreactivity was visualized with 3,3′-
diaminobenzidine tetrahydrochloride. Sections were coun-
terstained with Mayer hematoxylin, permanently mounted,
and viewed with a standard light microscope.
The normal staining pattern for DNMTs is nuclear, and a
case was considered positive only in the presence of nuclear
staining cells. A case was considered negative for expression
of DNMTs only when there was a complete absence of
nuclear staining cells in the presence of an unquestionable
internal positive control represented by normal epithelial cells
or stromal lymphocytes. For negative control preparations,
primary antibodies were omitted and replaced by TBS. In all
cases, immunostaining results were evaluated independently
by 2 pathologists (M. T. and S. Z.) using a semiquantitative
scoring system [20] taking into consideration the staining
3DMNTs and breast cancerintensity obtained (0, negative; 1, mild; 2, moderate; 3, high)
and the proportion of positive cells observed (0, negative; 1,
≤10%; 2, 11% to ≤33%; 3, 34% to ≤66%; 4, ≥66%). The 2
scores were then added for each slide, and overexpression
was deﬁned as grade 6 or greater.
2.3. Methylation-specific polymerase
chain reaction
The methylation status of the promoters on 8 tumor
suppressor genes was determinate by methylation-speciﬁc
polymerase chain reaction (PCR) arrays as previously
described [18]. Brieﬂy, genomic DNA was isolated from
fresh-frozen tumor samples by phenol/chloroform preceding
proteinase K treatment. The extracted nucleic acid was
examined by electrophoresis, and the yield was measured
spectrophotometrically on a Biophotometer (Eppendorf,
Hamburg, Germany) before use and stored at −20°C.
Extracted DNA was assessed for its suitability for PCR
analysis by a control reaction designed to amplify a fragment
of 407 bp of the β-globin gene as described previously [21].
Bisulﬁte conversion of genomic DNA was performed as
described previously by Herman et al [22]. This process
converts unmethylated cytosine residues to uracil, whereas
methylated cytosine residues remain unchanged. Bisulﬁte-
modiﬁed DNA was used as a template, and methylation-
speciﬁc PCR was performed to determine the methylation
status for 8 tumor suppressor genes involved in cell-cycle
regulation (P16 and RASSF1A) [23,24], cell adhesion and
invasion (CDH1 and TIMP3) [25,24], DNA repair
(BRCA1and BRCA2) [26,27], apoptosis (DAPK) [28], and
hormone receptor–mediated cell signaling (RARβ2) [24].
The PCR ampliﬁcation was performed with treated
DNA as template in a total volume of 25 μL containing
0.25 μmol/L of each primer pair, 200 μmol/L of each
dNTP, Tris-HCl (pH 8.3), 50 mmol/L KCl, 2.5 mmol/L
MgCl2, 5% dimethylsulfonide (DMSO), and 1 unit of Taq
DNA polymerase (Promega, Madison, WI, USA). Ampliﬁ-
cation was performed in a PTC 200 DNA engine thermal
cycler (MJ Research, Watertown, MA). Ampliﬁed products
were electrophoresed, using 2% agarose gel stained with
ethidium bromide, against a 50-bp DNA ladder (Promega),
and the images were captured under ultraviolet light using the
GelDoc2000 System (Bio-Rad, Marnes-la-Coquette,
France). All experiments were performed at least 2 times.
Tumors were categorized according to the number of
methylated genes into 2 groups: high-methylated group
(tumors showing N4 methylated genes) and low-methylated
group (tumors showing ≤4 methylated genes).
2.4. Statistical analysis
Statistical analysis was carried out with the SPSS
software package (version 17.0; SPSS, Chicago, IL).
Pairwise correlations between DNMTs overexpression andclinicopathologic parameters and methylation status were
investigated by χ2 test or Fisher exact test, where
appropriate. Probability values of P b .05 were regarded
as statistically signiﬁcant.3. Results
3.1. DNMT overexpression and
clinicopathologic parameters
By immunohistochemical analysis, overexpression of
DNMT1, DNMT3a, and DNMT3b was observed in 44
(46.8%), 30 (32%), and 42 (44.7%) of the 94 breast
carcinoma cases respectively investigated. Representative
results for DNMT1, DNMT3a, and DNMT3b staining are
shown in Fig. 1.
Fig. 2 summarizes the differential expression of DNMTs
in breast carcinomas. Overall, no signiﬁcant correlations
were found between the overexpression of these enzymes.
However, the 3 enzymes were simultaneously overexpressed
in 11.7% of cases. Coexpression of DNMT1 and DNMT3b
was found in 12.7% of cases. Coexpression of DNMT1 and
DNMT3a was noted in 6.3% of cases; the same frequency
was found for DNMT3a and DNMT3b coexpression.
With regard to clinicopathologic parameters (Table 1),
DNMT1 overexpression was signiﬁcantly associated with
SBR histologic grade III (P = .01), whereas DNMT3a
overexpression correlated signiﬁcantly with menopausal
status (P = .01), SBR histologic grade III (P = .0001), ER
(P = .04) and PR (P = .007) negativity, and HER2
overexpression (P = .004). However, no signiﬁcant correla-
tion was observed between DNMT3b overexpression and
any of the clinicopathologic parameters analyzed.
Table 2 shows the relationship between DNMT over-
expression and intrinsic tumor subtypes. No signiﬁcant
differences in DNMT1 and DNMT3b overexpression were
detected between the different intrinsic subtypes. However,
we found signiﬁcantly more frequent DNMT3a overexpres-
sion in luminal B (53%), HER2 (41%), and triple negative
(50%) groups than in luminal A (9.7%) (P = .001).
3.2. DNMT overexpression and
DNA hypermethylation
Promoter hypermethylation of BRCA1, BRCA2,
RASSF1A, TIMP3, CDH1, P16, RARβ2, and DAPK genes
were detected in 61 (65%), 64 (68%), 74 (79%), 18 (19%),
42 (45%), 35 (37%), and 35 (37%) of the 94 breast tumors
cases, respectively.
Table 3 summarizes the relationships between the
methylation status of these genes and DNMT overexpression.
No signiﬁcant correlation was found between promoter




Fig. 1 Immunohistochemical staining patterns of DNMT1, DNMT3a, and DNMT3b protein expression in breast carcinomas (original
magniﬁcation ×400). A-C, Representative examples of positive immunostaining for DNMT1 (A), DNMT3a (B), and DNMT3b (C). Note the
intense and diffuse positivity in the nuclei of tumor cells compared with normal acini (lower right corner of ﬁgures). D-F, Representative
examples of negative immunostaining for DNMT1 (D), DNMT3a (E), and DNMT3b (F).
4 R. Ben Gacem et al.overexpression of DNMT1 or DNMT3a. However, DNMT3b
overexpression correlated signiﬁcantlywith the hypermethyla-
tion of BRCA1 (P = .03) and RASSF1A (P = .04).
We also examined the relationship between the methyl-
ation of multiple genes and DNMT overexpression. We
found that 34% of our cases belong to the high-methylated
group (more than 4 genes methylated) and 66% belong to the
low-methylated group. No correlation was found between
the number of methylated genes and the overexpression of
DNMT1 and DNMT3a, whereas a signiﬁcant association
was found between DNMT3b overexpression and the high-
methylated group (P = .01) (Table 3).4. Discussion
Aberrations in DNA methylation are common in cancers
and have important roles in breast tumor initiation and
progression [3,18]. Dysregulated expression of the 3
functional DNMTs, which catalyze cytosine methylation,
may therefore be important in dysregulating gene expression,
especially of tumor suppressor genes during breast tumor-
igenesis. The aim of our current study was to investigate the
overexpression of DNMT1, DNMT3a, and DNMT3b using
immunohistochemistry in a series of 94 sporadic breast
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Fig. 2 Venn diagram of DNMT1, DNMT3a, and DNMT3b
differential overexpression in breast carcinoma.
Table 1 Association between DNMTs overexpression and
clinicopathologic parameters







≤45 44 23 (52) 18 (40) 17 (38)
N45 50 21 (42) 12 (25) 25 (50)
P value .31 .07 .26
Menopausal status
Pre- 51 23 (45) 21 (41) 21 (41)
Post- 43 21 (49) 8 (18) 22 (51)
P value .71 .01⁎ .33
Tumor grade a
Grade I 17 3 (17) 2 (11) 8 (47)
Grade II 36 17 (47) 5 (13) 13 (36)
Grade III 41 24 (58) 23 (56) 21 (51)
P value .01⁎ .0001⁎ .40
Tumor size (mm)
≤20 19 8 (42) 7 (36) 9 (47)
N20 75 36 (48) 23 (30) 33 (44)
P value .64 .60 .79
Lymph node involvement b
Negative 34 20 (59) 12 (35) 18 (53)
Positive 42 16 (38) 12 (28) 18 (43)
P value .07 .53 .38
ER status c
Negative 55 24 (43) 22 (40) 23 (41)
Positive 39 20 (51) 8 (20) 19 (48)
P value .46 .04⁎ .50
PR status c
Negative 50 24 (48) 22 (44) 26 (52)
Positive 44 20 (45) 8 (18) 16 (36)
P value .80 .007⁎ .14
HER2 status d
Negative 69 30 (43) 18 (26) 32 (46)
Positive 25 14 (56) 12 (48) 10 (40)
P value .28 .04⁎ .58
NOTE. P value for χ2 or Fisher exact test; asterisks indicate signiﬁcant
correlations.
a SBR classiﬁcation.
b Pathologic nodal status was missing in 18 cases.
c ER and PR receptors status was evaluated by immunohistochemistry
and considered positive if 10% or greater of tumor cells showed
nuclear staining.
d Evaluated by immunohistochemistry and considered positive if
scored 2+ or 3.
5DMNTs and breast canceroverexpression with clinicopathologic parameters and
hypermethylation of 8 tumor suppressor genes.
We found that DNMT1, DNMT3a, and DNMT3b are
frequently overexpressed in Tunisian breast cancer (46.8%,
32%, and 44.7% of cases, respectively). To date, only a
small number of studies have investigated DNMT expres-
sion in breast cancers. These studies have shown variable
rates of expression for DNMTs in breast cancers. Overall,
the levels of DNMT1, DNMT3a, and DNMT3b messenger
RNA (mRNA)/protein in breast carcinomas are signiﬁcantly
higher than in noncancerous breast tissues, and the highest
expression range was observed with DNMT3b [10,16].
Indeed, Girault et al [10] have reported a predominant role of
DNMT3b in breast tumorigenesis, relative to DNMT1 and
DNMT3a. DNMT3b overexpression was observed in 30%;
in contrast, only 5.4% and 3.1% of the patients' tumors
overexpressed DNMT1 and DNMT3a, respectively. How-
ever, Butcher and Rodenhiser [16] have found that
DNMT3b was overexpressed in 80% of the tumor cases.
The different levels of DNMT expression could be largely
caused by breast tumor heterogeneity and the diversity of
research methodologies.
In fact, all DNMTs have homology and different
functions [10]. DNMT1 maintains established methylation
patterns in hemimethylated genes by copying methylation
patterns from the parent strand to the daughter and is
expressed during the S-phase [29]. DNMT3a and DNMT3b,
referred to as de novo methyltransferases, methylate
unmethylated DNA. They initiate normal DNA methylation
during embryonic development [10].
With regard to clinicopathologic parameters, we found a
signiﬁcant relationship between DNMT1 overexpression
and high SBR histologic grade (P = .01). The above
evidence indicates that increased DNMT1 expression may
play a role in the malignant progression. To our knowledge,only 1 previous study has examined the expression of
DNMT1 in breast carcinomas. Using real-time reverse
transcription–PCR, Girault et al [10] have found that
DNMT1 was overexpressed in only a few tumors (5.6%),
but the authors did not check their result by immunohis-
tochemistry. Using real-time PCR and Western blot
techniques, Xiong et al [30] have found increased
DNMT1 expression in grade III endometrioid cancers. In
addition, and by immunohistochemistry, DNMT1 expres-
sion was found to be increased signiﬁcantly in high-grade
hepatocellular carcinomas, suggesting that DNMT1
Table 2 Correlation between DNMTs overexpression and intrinsic subtypes in breast carcinomas
Intrinsic histologic subtypes Total DNMT1, n (%) DNMT3a, n (%) DNMT3b, n (%)
Luminal A (ER/PR+, HER2−) 41 17 (41) 4 (9.7) 18 (43)
Luminal B (ER/PR+, HER2+) 13 8 (61) 7 (53) 5 (38)
HER2 overexpressing (ER−, PR−, HER2+) 12 6 (50) 5 (41) 5 (41)
Triple negative (ER−, PR−, HER2−) 28 13 (46) 14 (50) 14 (50)
P value .64 .001⁎ .90
NOTE. P value for χ2 or Fisher exact test; asterisks indicate signiﬁcant correlations.
6 R. Ben Gacem et al.overexpression plays a role in the early stage of
hepatocarcinogenesis [20]. Using semiquantitative reverse
transcription–PCR, Chen et al [9] have demonstrated that
DNMT1 overexpression in ovarian epithelial cancers was
correlated with low tumor differentiation, advanced clinical
stage, and lymphatic metastasis. By using immunohisto-
chemistry, a signiﬁcant correlation was reported between
DNMT1 overexpression and higher-stage tumors in 63
gastroenteropancreatic neuroendocrine tumors, suggesting
that the overexpression of DNMT1 was related to
tumorigenesis and progression of these tumors [11].
However, given the limited studies exploring the DNMT1




Unmethylated 33 13 (39)
Methylated 61 31 (50)
BRCA2 .19
Unmethylated 30 17 (56)
Methylated 64 27 (42)
RASSFA1 .23
Unmethylated 20 7 (35)
Methylated 74 37 (50)
TIMP3 .76
Unmethylated 76 35 (46)
Methylated 18 9 (50)
CDH1 .16
Unmethylated 52 21 (40)
Methylated 42 23 (54)
P16 .86
Unmethylated 50 23 (46)
Methylated 44 21 (47)
RARβ2 .79
Unmethylated 59 27 (45)
Methylated 35 17 (48)
DAPK .87
Unmethylated 59 28 (47)
Methylated 35 16 (45)
Methylated genes .12
≤4 genes 62 25 (40)
N4 genes 32 19 (59)
NOTE. P value for χ2 or Fisher exact test; asterisks indicate signiﬁcant correlatbetter elucidate the precise clinical signiﬁcance of DNMT1
expression in this cancer.
By examining the relationship between DNMT3a over-
expression and clinicopathologic parameters, we found
signiﬁcant correlations with menopausal status (P = .01),
SBR histologic grade III (P = .0001), ER (P = .04) and PR
(P = .007) negativity, and HER2 overexpression (P = .004);
this observation suggests that DNMT3a overexpression
may be a speciﬁc marker of tumor aggressiveness and
proliferation and also that it may play an important role in
breast carcinogenesis. Unfortunately, no previous study has
examined the relationship between DNMT3a overexpres-
sion and clinicopathologic parameters in breast carcinomas.moter hypermethylation
DNMT3a DNMT3b
n (%) P n (%) P
.82 .03⁎
11 (33) 10 (30)
19 (31) 32 (52)
.22 .28
7 (23) 11 (36)
23 (35) 31 (48)
.15 .04⁎
9 (45) 5 (25)
21 (28) 37 (50)
.67 .11
25 (32) 31 (40)
5 (27) 11 (61)
.28 .74
19 (36) 24 (46)
11 (26) 18 (42)
.64 .57
17 (34) 21 (42)
13 (29) 21 (47)
.59 .55
20 (33) 25 (42)
10 (28) 17 (48)
.32 .55
21 (35) 25 (42)
9 (25) 17 (48)
.13 .01⁎
23 (37) 22 (35)
7 (21) 20 (62)
ions.
7DMNTs and breast cancerHowever, DNMT3a overexpression was also found to be
associated with tumor aggressively in other types of
cancers. Indeed, a signiﬁcant correlation between
DNMT3a protein expression and higher tumor stage was
reported in gastroenteropancreatic neuroendocrine tumors
[11]. Moreover, a poorer recurrence-free survival was noted
in hepatocarcinomas with increased DNMT3a mRNA [12].
In our current study, we found that DNMT3a over-
expression is signiﬁcantly correlated with triple-negative
breast carcinomas and tumors overexpressing HER2 (P =
.001). Triple-negative carcinomas are themselves a subgroup
of “basal-type” breast tumors and account for 10% to 17% of
all breast cancers. These carcinomas are characterized by a
poor prognosis compared with tumors that are positive for
hormone receptors. Despite being sensitive to chemotherapy,
many women with triple-negative breast carcinomas relapse
quickly and commonly develop visceral metastases, includ-
ing lung, liver, and brain metastases. Combinations of
epigenetic drug treatments, especially DNMT inhibitors,
could potentially work synergistically in increasing thera-
peutic effects and may have important therapeutic implica-
tions in this subtype of cancer [13-15,31].
We found no link between DNMT3b overexpression and
any of the clinicopathologic parameters analyzed in our
present study. Few trials have been performed on solid
tumors to investigate DNMT3b expression in breast
carcinomas. Butcher and Rodenhiser [16] have examined
DNMT3b expression by immunohistochemistry in a series of
54 sporadic breast carcinomas from Canada and reported a
high frequency of DNMT3b overexpression (80% of cases),
but the authors did not seek any relationship of their results
with clinicopathologic parameters. The only previous study
that examined the relationship between DNMT3b expression
and clinicopathologic parameters in breast carcinomas was
that described by Girault et al [10]. Using real-time PCR, the
authors found that DNMT3b mRNA overexpression is
signiﬁcantly associated with high SBR histologic grade,
ER negativity, and strong expression of the proliferation
marker Ki-67, but not with patients' age, menopausal status,
lymph node involvement, or macroscopic tumor size. They
also found an association between DNMT3b overexpression
and poor relapse-free survival in patients who received
adjuvant hormone therapy in univariate analysis. The authors
of this study suggested that DNMT3b may be a marker of
both tumor aggressiveness and proliferation.
In the present study, we also investigated the relationship
between DNMT overexpression and DNA methylation. We
found no correlation between overexpression of DNMT1 or
DNMT3a and promoter hypermethylation of the tumor
suppressor genes investigated. Although more CpG islands
still need to be examined to draw conclusions, the lack of
correlation between expression of these enzymes and DNA
methylation in this study implies that increased DNMT1 and
DNMT3a expression in breast cancer may have other roles
during breast carcinogenesis than merely altering DNA
methylation of tested genes. In the absence of previousstudies exploring the expression of DNMT1 and DNMT3a in
breast cancer and their relation to DNA methylation, we
cannot draw consistent conclusions about the role of these 2
enzymes in DNAmethylation. Other studies analyzing larger
series of breast cancer and taking into account the
methylation status of a larger number of tumor-related
genes are required to clarify the role of these enzymes in
breast carcinogenesis.
With regard to DNMT3b, few signiﬁcant relationships
were found in our study. Indeed, DNMT3b overexpression
correlates signiﬁcantly with hypermethylation of BRCA1
(P = .03) and RASSF1A (P = .04) in our series of cases.
This suggests that DNMT3b may be the primary DNMT
responsible for methylation of these 2 critical genes. The
subsequent epigenetic alteration of BRCA1 activity would
predispose a cell to tumorigenesis, because of defects in
BRCA1-dependent DNA repair, and cycle regulation and
proliferation [16]. RASSF1A regulates several biological
processes including cell cycle progression, apoptosis, and
microtubule stability. It is currently thought that RASSF1A
functions as a scaffold for the assembly of multiple tumor
suppressor complexes and may relay proapoptotic signaling
by K-RAS. Several reports indicate the presence of aberrant
methylation in RASSF1A in various types of human tumors
[32-34]. Promoter hypermethylation of BRCA1 and
RASSF1A is common in sporadic ovarian cancer [33].
Furthermore, Gao et al [34] conﬁrmed that the presence of
a RASSF1A functional polymorphism was associated with
breast cancer pathogenesis in general and modiﬁed breast
cancer age of onset in BRCA1/2 mutation carriers.
Data on the existence of a hypermethylator phenotype in
breast cancer are controversial [35]. There is no standard
deﬁnition of highly methylated tumors that most likely
represent the hypermethylator phenotype. In the present
study, we examined the relationship between multigene
methylation and DNMT overexpression. We found that 34%
of our cases belong to the high-methylated group (more than
4 genes methylated). Moreover, we found a signiﬁcant
association between DNMT3b overexpression and the high-
methylated group (P = .01). These ﬁndings support the
existence of a hypermethylator phenotype in breast cancer
and suggest a role for DNMT3b in this phenotype.
Epigenetic changes are reversible, raising the possibility
that inhibition of speciﬁc enzymes that regulate epigenetic
marks would have antitumor effects. Promoter methylation
can be reversed by using DNMT inhibitors, such as 5-aza-2′-
deoxycytidine-decitabine or 5-aza-cytidine [13-15]. These
molecules are metabolized intracellularly to 5-aza-2′-deoxy-
cytidine-triphosphate, which is incorporated into DNA in
place of 2′-deoxycytidine-triphosphate. This results in the
covalent binding of DNMT1, DNMT3a, and DNMT3b to
modiﬁed DNA; inhibition of DNMT activity; and DNMT
degradation. The use of these epigenetic drugs allows
restoration of the expression of genes that are silenced by
hypermethylation in breast cancer and thus restores normal
cell growth control or induces apoptosis in tumor cells. These
8 R. Ben Gacem et al.agents will be effective especially in breast cancer over-
expressing DNMTs with multiple methylated genes and may
help patients to live longer with fewer side effects than is
possible with standard chemotherapy.
In conclusion, we found that DNMTs are frequently
overexpressed in sporadic breast carcinomas and correlate
signiﬁcantly with promoter hypermethylation of multiple
tumor suppressor genes and aggressive forms of Tunisian
breast cancer. These data suggest that overexpression of
various DNMTs might represent a critical event responsible
for the epigenetic inactivation of several tumor suppressor
genes and lead to the development of breast cancers,
especially those with aggressive phenotype.References
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